Recombinant Thyrotropin <i>vs</i> Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod)

Leenhardt, Laurence; Leboulleux, Sophie; Bournaud, Claire; Zerdoud, Slimane; Schvartz, Claire; Ciappuccini, Renaud; Kelly, A.; Morel, Olivier; Dygai‐Cochet, Inna; Rusu, Darian; Chougnet, C.; Lion, Georges; Eberle-Pouzeratte, M.C.; Catargi, Bogdan; Kabir-Ahmadi, Marmar; Feuillet, Eliane Le Peillet; Taïeb, David

doi:10.1210/jc.2018-01589

Cited by 13 publications

(17 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there is a trend toward higher ablation rates with higher activities in patients with large thyroid remnants as observed in the past, similar rates of successful remnant ablation have been reported using activities ranging from 1110 to 3700 MBq of I-131 ( 47 , 48 , 49 , 50 ). A randomized study using preparation with rhTSH showed that ablation rates were comparable with 1850 MBq or 3700 MBq ( 47 ).…”

Section: Activity Of I-131 To Be Employed For Post-surgical Thyroid R...supporting

confidence: 72%

“…The remnant ablation rate was similar in all groups irrespective of the TSH stimulation method used, and the authors concluded that recombinant human thyrotropin is equally effective for preparation for remnant ablation in low-risk patients. In addition, shortterm recurrence rates have been found to be similar in patients prepared with thyroid hormone withdrawal or rhTSH, both in low (11,48) and intermediate-risk patients (49,50). Furthermore the preparation with rhTSH is associated with an unimpaired quality of life (46,51), and reduces both the whole body radiation absorbed dose (38,39) and duration of hospitalization (6,41,43,52).…”

Section: Preparation For Rai Administrationmentioning

confidence: 96%

See 1 more Smart Citation

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

Pacini

Führer

Elisei

et al. 2022

European Thyroid Journal

Self Cite

View full text Add to dashboard Cite

Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patients’ risk stratification. Although beneficial effects of radioiodine are undisputed in high-risk patients, controversy remains in intermediate-risk and some low-risk patients. Since the last consensus on post-surgical use of RAI in DTC patients, new retrospective data and results of prospective randomized trials have been published, which have allowed the development of a new European Thyroid Association (ETA) statement for the indications of post-surgical RAI therapy in DTC. Questions about which patients are candidates for RAI therapy, which activities of RAI can be used, and which modalities of pre-treatment patient preparation should be used are addressed in the present guidelines.

show abstract

Section: Activity Of I-131 To Be Employed For Post-surgical Thyroid R...supporting

confidence: 72%

Section: Preparation For Rai Administrationmentioning

confidence: 96%

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

Pacini

Führer

Elisei

et al. 2022

European Thyroid Journal

Self Cite

View full text Add to dashboard Cite

show abstract

“…Also, in iodine-deficient countries, those tumors are often an incidental finding after surgery for goiter. Given the fairly high percentage of lymph node metastases even in pT1a (12-50%, according to Perros et al [10]), radioiodine treatment in low-intermediate risk tumors in many cases will have an adjuvant approach, besides ablative aspects [11].…”

Section: Low-risk Dtcmentioning

confidence: 99%

SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management—the EANM perspective

Ovčariček

Kreißl

Campennì

et al. 2022

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…In patients with a higher risk of recurrence, where RAI is being used as adjuvant therapy, rhTSH may be 'considered as an alternative to THW'. At our institution, as is similar at many institutions with large thyroid tumor programs, we almost exclusively use rhTSH preparation for patients being treated as adjuvant therapy and remnant ablation, based on multiple short-term follow-up studies (Mallick et al 2012b, Schlumberger et al 2012, Pak et al 2014, Tu et al 2014, Leenhardt et al 2019. Patients who are at high risk for recurrence need individualized decision-making about using rhTSH or THW since the evidence is more limited in this subgroup (Tala et al 2011, Klubo-Gwiezdzinska et al 2012, Iizuka et al 2020.…”

Section: Logistical Considerationsmentioning

confidence: 99%

Tailoring the approach to radioactive iodine treatment in thyroid cancer

Mayson

Chan

Haugen

2021

Endocrine-Related Cancer

View full text Add to dashboard Cite

The treatment of differentiated thyroid cancer continues to move away from a ‘one size fits all’ approach to a process of tailored therapeutic decision-making that incorporates disease-specific factors and individual patient preferences. Management options range from active surveillance to thyroid lobectomy to total thyroidectomy with or without the use of postoperative radioactive iodine (RAI). RAI may be administered for one or more reasons: Thyroid remnant ablation, adjuvant therapy, or therapy for persistent structural disease. It is important to be cognizant of the therapeutic intent of RAI and weigh the risks and benefits of treatment for each individual patient. Risk stratification should be used to identify those patients who are most likely to benefit from RAI and guide therapeutic choices. Available data suggest that RAI can be safely deferred for most patients considered at low risk for structural recurrence, while adjuvant RAI is associated with improved disease-free survival in patients with higher risk disease. Although progress has been made, many areas of uncertainty related to the use of RAI remain. These include: 1) The appropriate selection of intermediate risk patients to receive adjuvant RAI, 2) the superiority or inferiority of different RAI dosing activities, 3) the optimal approach to the use of RAI in special populations, including patients with ESRD and children and 4) the management of patients with RAI-refractory disease.

show abstract

Recombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod)

Cited by 13 publications

References 29 publications

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management—the EANM perspective

Tailoring the approach to radioactive iodine treatment in thyroid cancer

Contact Info

Product

Resources

About